Cetuximab/targeted chemotherapy in an HIV-positive patient with metastatic colorectal cancer in the HAART era: A case report

M. Berretta, F. Martellotta, C. Simonelli, F. Di Benedetto, N. De Ruvo, A. Drigo, A. Bearz, M. Spina, E. Zanet, S. Berretta, Umberto Tirelli

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Recent data have shown the efficacy of cetuximab/Folfiri regimen in patients with chemotherapy-resistant metastatic colorectal cancer. In the literature there are no data about this treatment in HIV-positive patients with metastatic colorectal cancer. At the Aviano Cancer Center, we used the cetuximab/Folfiri regimen and concomitant HAART in an HIV-positive patient with metastatic colorectal cancer. The patient experienced acceptable non-hematological toxicity, without any opportunistic infection and his HIV infection was kept under control. This case suggests that, in the HAART era, a multidisciplinary approach can be offered to HIV patients with advanced cancer when they have good performance status, resulting in efficacious control of the HIV infection.

Original languageEnglish
Pages (from-to)343-346
Number of pages4
JournalJournal of Chemotherapy
Volume19
Issue number3
Publication statusPublished - Jun 2007

Fingerprint

Highly Active Antiretroviral Therapy
Colorectal Neoplasms
HIV
Drug Therapy
HIV Infections
Opportunistic Infections
Neoplasms
Cetuximab

Keywords

  • Cetuximab
  • Colorectal cancer
  • Folfiri
  • HAART
  • HIV

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Microbiology (medical)

Cite this

Berretta, M., Martellotta, F., Simonelli, C., Di Benedetto, F., De Ruvo, N., Drigo, A., ... Tirelli, U. (2007). Cetuximab/targeted chemotherapy in an HIV-positive patient with metastatic colorectal cancer in the HAART era: A case report. Journal of Chemotherapy, 19(3), 343-346.

Cetuximab/targeted chemotherapy in an HIV-positive patient with metastatic colorectal cancer in the HAART era : A case report. / Berretta, M.; Martellotta, F.; Simonelli, C.; Di Benedetto, F.; De Ruvo, N.; Drigo, A.; Bearz, A.; Spina, M.; Zanet, E.; Berretta, S.; Tirelli, Umberto.

In: Journal of Chemotherapy, Vol. 19, No. 3, 06.2007, p. 343-346.

Research output: Contribution to journalArticle

Berretta, M, Martellotta, F, Simonelli, C, Di Benedetto, F, De Ruvo, N, Drigo, A, Bearz, A, Spina, M, Zanet, E, Berretta, S & Tirelli, U 2007, 'Cetuximab/targeted chemotherapy in an HIV-positive patient with metastatic colorectal cancer in the HAART era: A case report', Journal of Chemotherapy, vol. 19, no. 3, pp. 343-346.
Berretta, M. ; Martellotta, F. ; Simonelli, C. ; Di Benedetto, F. ; De Ruvo, N. ; Drigo, A. ; Bearz, A. ; Spina, M. ; Zanet, E. ; Berretta, S. ; Tirelli, Umberto. / Cetuximab/targeted chemotherapy in an HIV-positive patient with metastatic colorectal cancer in the HAART era : A case report. In: Journal of Chemotherapy. 2007 ; Vol. 19, No. 3. pp. 343-346.
@article{0b5f2c36edbf4bd5a0ff9affa42b4b0e,
title = "Cetuximab/targeted chemotherapy in an HIV-positive patient with metastatic colorectal cancer in the HAART era: A case report",
abstract = "Recent data have shown the efficacy of cetuximab/Folfiri regimen in patients with chemotherapy-resistant metastatic colorectal cancer. In the literature there are no data about this treatment in HIV-positive patients with metastatic colorectal cancer. At the Aviano Cancer Center, we used the cetuximab/Folfiri regimen and concomitant HAART in an HIV-positive patient with metastatic colorectal cancer. The patient experienced acceptable non-hematological toxicity, without any opportunistic infection and his HIV infection was kept under control. This case suggests that, in the HAART era, a multidisciplinary approach can be offered to HIV patients with advanced cancer when they have good performance status, resulting in efficacious control of the HIV infection.",
keywords = "Cetuximab, Colorectal cancer, Folfiri, HAART, HIV",
author = "M. Berretta and F. Martellotta and C. Simonelli and {Di Benedetto}, F. and {De Ruvo}, N. and A. Drigo and A. Bearz and M. Spina and E. Zanet and S. Berretta and Umberto Tirelli",
year = "2007",
month = "6",
language = "English",
volume = "19",
pages = "343--346",
journal = "Journal of Chemotherapy",
issn = "1120-009X",
publisher = "Maney Publishing",
number = "3",

}

TY - JOUR

T1 - Cetuximab/targeted chemotherapy in an HIV-positive patient with metastatic colorectal cancer in the HAART era

T2 - A case report

AU - Berretta, M.

AU - Martellotta, F.

AU - Simonelli, C.

AU - Di Benedetto, F.

AU - De Ruvo, N.

AU - Drigo, A.

AU - Bearz, A.

AU - Spina, M.

AU - Zanet, E.

AU - Berretta, S.

AU - Tirelli, Umberto

PY - 2007/6

Y1 - 2007/6

N2 - Recent data have shown the efficacy of cetuximab/Folfiri regimen in patients with chemotherapy-resistant metastatic colorectal cancer. In the literature there are no data about this treatment in HIV-positive patients with metastatic colorectal cancer. At the Aviano Cancer Center, we used the cetuximab/Folfiri regimen and concomitant HAART in an HIV-positive patient with metastatic colorectal cancer. The patient experienced acceptable non-hematological toxicity, without any opportunistic infection and his HIV infection was kept under control. This case suggests that, in the HAART era, a multidisciplinary approach can be offered to HIV patients with advanced cancer when they have good performance status, resulting in efficacious control of the HIV infection.

AB - Recent data have shown the efficacy of cetuximab/Folfiri regimen in patients with chemotherapy-resistant metastatic colorectal cancer. In the literature there are no data about this treatment in HIV-positive patients with metastatic colorectal cancer. At the Aviano Cancer Center, we used the cetuximab/Folfiri regimen and concomitant HAART in an HIV-positive patient with metastatic colorectal cancer. The patient experienced acceptable non-hematological toxicity, without any opportunistic infection and his HIV infection was kept under control. This case suggests that, in the HAART era, a multidisciplinary approach can be offered to HIV patients with advanced cancer when they have good performance status, resulting in efficacious control of the HIV infection.

KW - Cetuximab

KW - Colorectal cancer

KW - Folfiri

KW - HAART

KW - HIV

UR - http://www.scopus.com/inward/record.url?scp=34447513675&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34447513675&partnerID=8YFLogxK

M3 - Article

C2 - 17594933

AN - SCOPUS:34447513675

VL - 19

SP - 343

EP - 346

JO - Journal of Chemotherapy

JF - Journal of Chemotherapy

SN - 1120-009X

IS - 3

ER -